You are here

Home » Content

DİSLİPİDEMİK ERİŞKİNLERDE, ANTİHİPERLİPİDEMİK İLAÇ TEDAVİLERİNİN OPTİMAL ETKİ VE NÖROLOJİK YAN ETKİ YÖNÜNDEN DEĞERLENDİRİLMESİ

Assessment the optimum efficacy and neurologic side effect(s) of antihyperlipidemic drug regimens in dyslipidemic adult patients

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Aim: To assess the optimum efficacy and neurological side effect(s) of antihyperlipidemic drug reg-imens in dyslipidemic adult patients. Material and Method: Fotry-two male, eighty-seven female; totally 129 dyslipidemic patients, 37 to 77 years of age who admitted to neurology and cardiology out-patient clinics were eligible for our study. All of the patients were recommended to reach an ideal body weight and to maintain a standard low-lipid diet. Patients were divided into 5 subgroups and were assigned to receive commonly used antihyperlipidemic agents; low-dose atorvastatin (10 mg), pravastatin (10 mg), simvastatin (10 mg), fenofibrate (200 mg) and a combination of fenofibrate and atorvastatin regimen. Neurological examination was evaluated besides fasting plasma lipid profile and muscle enzyme levels at 0, 3, 6 and 12-month intervals. Electroneuromyography (ENMG) was per-formed in patients having neurological complaint(s), finding(s) and/or elevated muscle enzyme le¬vels after drug administration. Results: According to ATP III criteria, in the second 6-month period, fenofibrate effectively improved the triglyceride profile in patients with high and borderline plasma lipid levels versus pravastatin therapy. In the first 3-month period, atorvastatin significanty improved LDL-C levels versus fenofibrate. In the first 6-month period, pravastatin caused a marked elevation of creatinine kinase levels versus atorvastatin. Among all the drugs, no other differences were observed either on lipid or on side effect profiles. No pathological findings were observed in patients who underwent ENMG. Conclusion: For the first year, low-dose antihyperlidemic agents have mostly similar efficacy profiles. Encountered side effects are; myalgia and elevated serum creatinine phos-phokinase (CPK) levels at a range of 4-68 %. CPK elevations did not exceed to 3 to 10 times as report¬ed in the literature with any of the drugs. In spite of myopathic changes in ENMG, myalgia was commonly reported. In conclusion we suggest that, patients at hig-risk, represent a suitable group for prolonged statin treatment with regular clinical follow-up.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Dispidemik erişkinlerde, antihiperlipidemik ilaç tedavilerinin optimal etki ve nörolojik yan etki yönünden araştırılması. Gereç ve Yöntem: Nöroloji ve kardiyoloji polikliniklerine başvuran 37-77 yaşları arasında 42 kadın, 87 erkek, toplam 129 dislipidemik hasta çalışmamız için seçildi. Tüm hasta¬lara, ideal kilolarına ulaşmaları ve standart lipidden fakir beslenme diyetini uygulamaları önerildi. Hastalar 5 gruba ayrıldı. Gruplara sık kullanılan antihiperlipidemik ilaçlardan; düşük doz atorvastatin (10 mg), pravastatin (10 mg), simvastatin (10 mg), fenofibrat (200 mg) ve fenofibrat + atorvastatin kombinasyonu başlandı. 0, 3, 6 ve 12. aylarda nörolojik muayene yapıldı ve kan lipit profili, kan en¬zimleri izlendi. ilaç kullanımı sonrası nörolojik şikayeti olanlara, nörolojik muayenesinde patolojik bulgu tespit edilenlere ve kas enzimleri yüksek olanlara ENMG yapıldı. Bulgular: ATP III Kriterlerine göre yüksek ve sınırlı yüksek hiperlipidemi vakalarında düşük doz antihiperlipidemik ilaç kullanımı sonucu; ikinci 6 ayda fenofibrat provastatine oranla anlamlı bir şekilde Trigliserit'de (TG) düşme sağladı. ilk 3 ayda atorvastatin fenofibrata oranla LDL-K değerlerine anlamlı bir düşmeye neden oldu. ilk 6 ayda pravastatin, atorvastatine oranla kreatin kinaz seviyelerinde anlamlı artışa neden oldu. Kullanılan ilaçlar arasında diğer lipit profilleri üzerine etkiler ve yan etkileri açısından bir fark yoktu. ENMG yapılan hastalarda patolojik bulgu gözlenmedi. Sonuç: Bir yıl süreyle düşük doz kullanılan antihiperlipidemik ilaçlar çoğunlukla etki bakımından benzer konumdadır. Kas enzimleri üzerine yan etkileri miyaji ve % 4-68 oranında enzim artışı şeklindedir. Tüm ilaçlar için CK artışı literatürde belir¬tilen 3-10 kat yüksekliğe ulaşmamıştır. ENMG'de miyopati olmamasına rağmen miyaji, önemli bir yakınma nedenidir. Sonuçta uzun süreli statin tedavisinin yüksek risk taşıyan ve düzenli kontrol edilebilen hastalarda önerilmesinin uygun olduğu kanısındayız.
FULL TEXT (PDF): 
PDF icon arastirmax-dislipidemik-eriskinlerde-antihiperlipidemik-ilac-tedavilerinin-optimal-etki-norolojik-yan-etki-yonunden-degerlendirilmesi.pdf
  • 1
17-23
  • Turkish

REFERENCES

References: 

1. Kannel WB, Thom TJ. Incidence, prevalence and mortality of cardiovascular disease. In: Schland RC, Alexander WR(eds.). Hurst's the Heart (8 th ed.) London, Mc.Graw-Hill Inc 1994:185-97
2. Eren N, Erzengin F. Koroner Kalp Hastalığında Risk Faktörü Olarak Dislipidemiler; Tedavide Yeni Pren¬sipler. MN Kardiyoloji 1994:1;86-94
3. Gök H. Klinik Kardiyoloji. istanbul, Nobel Tıp Kita-bevleri Ltd. fiti. 1996:97-107
4. The Expert Panel: Report of the National Choleste¬rol Education Program expert panel on Detection, Evaluation, and Treatment of High Blood Choles¬terol in Adults. Arch Intern Med 1998; 148: 36-39.

5. Bilheimer DW.Disorders of Lipid Metabolism. Text¬book of Internal Medicine, Edited by, Kelley, WN, De Vita, VT Jr, Dupont, HL. Philedelphia: Lippin-cont 1989: 2258-69.
6. Sinzinger H. Statin-induced myositis migrans. Wi¬en Klin Wochenschr 2002;114:943-4
7. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol con-centrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA). a multicentre randomised controlled trial Lancet 2003;361:1149-58.

8. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet. 1998;352:1801-7.
9. Crouse JR 3rd, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk re¬duction: an analysis of clinical trials data Athe¬rosclerosis 1998;138:11-24.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin Survival Study (4S). Lancet
1994;344:1383-9.
11. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer
MA, Bernstein V, et al. Reduction of stroke inciden¬ce after myocaardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation 1999;99:216-23.
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart di¬sease and a broad range of initial cholesterol le¬vels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.

13. Onat A, Tokgözoğlu L, Soydan i, Sansoy V. Higher efficacy of 10 mg/day of simvastatin in Turkish pa¬tients with hyperlipidemia. Türk Kardiyol Der
2000;28:635-42.
14. Kayıkçıoğlu M, Can HL, Özerkan F, Kültürsay H. Tip 2 kombine hiperlipidemi olgularında fibrat tedavi¬sinin lipid profili, C-Reaktif Protein ve fibrinojen dü¬zeylerine etkisi. Türk Kardiyol Dern 2002;30:88-92.
15. Lev EI, Tur-Kaspa I, Ashkenazy I, Reiner A, Faraggi D, Shemer J, et al. Distribution of serum creatine kinase activity in young healthy persons. Clin Chim Acta 1999;279:107-15.
16. Hodel C. Myopathy and rhabdomyolysis with li-pid-lowering drugs. Toxicol Lett 2002;128:159-
68.
17. Guis S, Mattei JP, Liote F. Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol
2003;17:877-907.
18. Simons M, Keller P, Dichgans J, Schulz JB. Choles-terol and Alzheimer's disease: is there a link? Ne-urology 2001;57:1089-93.

Thank you for copying data from http://www.arastirmax.com